Belmora Melox Agrura

Calcium Carbonate


Belmora, Llc
Human Otc Drug
NDC 27854-120
Belmora Melox Agrura also known as Calcium Carbonate is a human otc drug labeled by 'Belmora, Llc'. National Drug Code (NDC) number for Belmora Melox Agrura is 27854-120. This drug is available in dosage form of Tablet, Chewable. The names of the active, medicinal ingredients in Belmora Melox Agrura drug includes Calcium Carbonate - 420 mg/1 . The currest status of Belmora Melox Agrura drug is Active.

Drug Information:

Drug NDC: 27854-120
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Belmora Melox Agrura
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Calcium Carbonate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Belmora, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet, Chewable
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CALCIUM CARBONATE - 420 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 03 Jun, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 05 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part331
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Belmora, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:313884
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0853030002663
UPC stands for Universal Product Code.
UNII:H0G9379FGK
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Blood Coagulation Factor [EPC]
Calcium [CS]
Cations
Divalent [CS]
Increased Coagulation Factor Activity [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
27854-120-0150 PACKET in 1 CARTON (27854-120-01) / 2 TABLET, CHEWABLE in 1 PACKET03 Jun, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose antacid

Product Elements:

Belmora melox agrura calcium carbonate croscarmellose sodium croscarmellose sorbitol magnesium stearate mineral oil aspartame maltodextrin calcium carbonate calcium cation carbonate ion az;036

Indications and Usage:

Uses relieves ■ acid indigestion ■ sour stomach ■ heartburn ■ upset stomach associated with these symptoms

Warnings:

Warnings

Do Not Use:

Warnings

When Using:

When using this product ■ do not take more than 19 tablets in a 24 hour period. if symptoms persist for more than two weeks, stop using this product and see a doctor.

Dosage and Administration:

Directions adults and children: (12 years and older) chew 2 tablets every 2-3 hours or as symptoms occur, repeat hourly if needed. do not exceed 19 tablets in 24 hours. children under 12 years: ask a doctor

Package Label Principal Display Panel:

Belmora melox ndc 27854-120-01 belmora llc melox agrura/heartburn chew or crush tablets completely before swallowing masticar o triturar completamente las tabletas antes de tragar antacid/calcium carbonate antiacido/carbonato de calcio heartburn, indigestion calcium carbonate 420mg las aguras, la indigestion carbonato de calco 420mg 100 tablets/50-dual packets/1 tablets per packet tamper evident unit dose packets/empacquetado con sellado evidente en dosis unitarias belmora

Further Questions:

Questions or comments? call 1-800-779-2877 m-f 9am-5pm est distributed by: belmora llc, 3033 wilson blvd. suite 700, arlington, va 22201 rev 02/2022


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.